The U.S. Food and Drug Administration (FDA) approved a new cancer-fighting drug for use by children with acute lymphoblastic leukemia (ALL). The medication is called "Telavancin", and it is the first antibiotic to be approved by the FDA for treating infections related to ALL. The medication, which was developed by drug giant Pfizer Inc., is an injection that can treat bacterial bloodstream infections known as . It will be administered through IV infusion and will cost about $750 per dose. The FDA's approval came with a warning to patients that the drug can cause heart attacks, and also warned of life-threatening skin reactions.
